Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis.
about
Fatty acid metabolites in rapidly proliferating breast cancerAn expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situExpression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancerInflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancerA systems approach to clinical oncology: focus on breast cancer.COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situAbalone visceral extract inhibit tumor growth and metastasis by modulating Cox-2 levels and CD8+ T cell activity.Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patientsSuppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells.Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients.Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progressionCytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancerRole of traditional and new biomarkers in breast carcinogenesis.COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirinRecent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort studyCaveolin-1 expression in benign and malignant lesions of the breast.Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ.Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoidClinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.Stromal biomarkers in breast cancer development and progression.Role of Aspirin in Breast Cancer Survival.Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.Influence of dexamethasone on mesenteric lymph node of rats with severe acute pancreatitis.Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs.The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes.
P2860
Q21090755-10C70C71-21B0-479C-8B28-41939EF883FEQ21195234-A6FD5244-5B4F-46DF-9BE0-502598A13F83Q24652752-48898B48-572D-4E5C-985C-7C8E73BBB1FFQ28218639-3E4C9ACF-076F-4FE6-BE73-AAC06022A40CQ33238889-59EAF322-DA9F-4DCF-BC0A-225E59FAA60AQ33317621-AE35BC10-633B-4BF5-B5B7-16464272A90EQ33723522-3E20DCED-FB5E-436F-A568-E40B88F424D6Q33932996-C0E4EFA4-1CC0-4B67-AE53-F57C346703EAQ34032403-31584EE3-F446-45EA-819C-4FE0942A6B64Q34316720-6FAD7F84-55BD-4445-8AD0-DD654CA935CCQ34452014-4356D5F1-C417-4FE2-860A-2E58E62B5553Q34543740-8F41A74E-2D20-4218-A21F-2E623D8C72B6Q34996098-47F37304-A030-4BEF-9E5C-0F30E6A5B469Q35108403-27FA9F80-4D1D-4E85-8F87-008A7A1F5DCAQ35572905-7EF18BB9-D864-40F5-98A6-A9C21C99D040Q35797114-9902081E-5A3F-48C9-9CAF-526EC48205F0Q35911030-2255A4E8-EC3C-4CC2-9B97-F9B037D17C4BQ36152220-38038030-5263-4293-9430-86D1D3CB9F7EQ36616905-33A89F09-AB3A-40B5-AA03-262C2EE81099Q37033840-42645C57-33B4-4F00-800B-E760DEE8D6DBQ37701526-6DB491B2-EFFA-4D43-8D44-B75221EB3AECQ38017601-E4B8FDC7-1CD3-4213-AF66-B2F57E6D62CAQ38735032-D42F336E-6E80-4D79-AAA5-F34BC41883CAQ40233359-16AC2134-A178-4996-BC49-637F0D44150AQ42588022-A2B03D59-2E67-49D7-BEE4-6D85CF491C75Q43061636-6D0DAD63-0EF2-42FC-8141-EA3DDE3DDF1AQ47273449-0D362523-666C-427C-B5B1-6BC66AB837F7Q53389613-1EB19F0B-7AD0-4293-A9AE-79132F259E98
P2860
Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Analysis of cyclooxygenase-2 e ...... ut tissue microarray analysis.
@en
Analysis of cyclooxygenase-2 e ...... ut tissue microarray analysis.
@nl
type
label
Analysis of cyclooxygenase-2 e ...... ut tissue microarray analysis.
@en
Analysis of cyclooxygenase-2 e ...... ut tissue microarray analysis.
@nl
prefLabel
Analysis of cyclooxygenase-2 e ...... ut tissue microarray analysis.
@en
Analysis of cyclooxygenase-2 e ...... ut tissue microarray analysis.
@nl
P2093
P1476
Analysis of cyclooxygenase-2 e ...... ut tissue microarray analysis.
@en
P2093
Achim Heinecke
Achim Rody
Christian Wülfing
Christine Müller
Ludwig Kiesel
Pia Wülfing
Raihanatou Diallo
Robert R Greb
Werner Böcker
P2888
P304
P356
10.1007/S00432-003-0459-1
P577
2003-07-15T00:00:00Z